国际标准期刊号: 2155-952X

生物技术与生物材料

开放获取

我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

索引于
  • 哥白尼索引
  • 谷歌学术
  • 夏尔巴·罗密欧
  • 打开 J 门
  • Genamics 期刊搜索
  • 学术钥匙
  • 研究圣经
  • 中国知网(CNKI)
  • 访问全球在线农业研究 (AGORA)
  • 电子期刊图书馆
  • 参考搜索
  • 哈姆达大学
  • 亚利桑那州EBSCO
  • OCLC-世界猫
  • SWB 在线目录
  • 虚拟生物学图书馆 (vifabio)
  • 普布隆斯
  • 日内瓦医学教育与研究基金会
  • 欧洲酒吧
  • ICMJE
分享此页面

抽象的

Unspoken risks and uncomfortable questions of stem cells in diabetes

EwaKozłowska

According to the World Health Organization’s statistics published in 2018, The number of people with diabetes has increased from 108 million in 1980 to 422 million in 2014 and still growing. Only in Poland the number of deaths attributable to high blood glucose in 2016 was estimated at 25 800. According to the internationally recognized definitions: Diabetes is a chronic condition that occurs when the pancreas can no longer make insulin, or when the body is unable to make effective use of the insulin it produces”. “Insulin is a pancreatic hormone that acts as a key to allowing glucose from the food we eat to pass from the blood stream into the body's cells to generate energy. All products made with carbohydrates are broken down into blood glucose. Insulin helps glucose get into the cells”. Not being able to produce or use insulin efficiently results in elevated blood glucose levels (known as hyper-glycemia). In the long term high levels of glucose are associated with body damage and degradation in specific organs and tissues. Over the years, several different therapeutic strategies have been investigated but none of them have proved to be completely successful. Scientists and doctors have found a way to save and extend the lives of patients, and continue to seek a way to achieve complete healing. Stem cells tend to be a new step in their journey toward development. or delayed, but still, a reliable method of complete recovery remains undiscovered. Cell-based therapies for beta-cell replacement are now under intensified investigation. Researchers have been advancing methods to generate insulin-producing beta cells from pluripotent stem cells (PSC) for the clinical treatment of diabetes. Although American researchers say, that once taken stem cells can be multiplied indefinitely; the use of stem cells from human embryos still raises ethical resistance. Apart from the steam cell ethical factors, physicians and scientists have more moral dilemma connected with the selection of patients for the treatment and possible risks. Mostly mentioned risks are tumors, the growth of the stem cells into unwanted cell types and taking immunosuppressive drugs that suppress the activity of the immune system. It is also difficult to regulate how much insulin the new beta cells produce. Other than that, the scientists tend to present the matter in bright colors. It may be difficult to predict the physical and psychological reaction of patients against a sudden "miracle cure". Stem cell treatment may become harmful to the good habits worked over the years. To some patients it may cause some kind of “breaking the leash” syndrome, especially those of type 2 diabetics, for who the cause of the disease was poor eating habits.